A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Daniel Peter Petrylak
Consultant or Advisory Role - Astellas Pharma; Dendreon
Research Funding - Astellas Pharma; Dendreon
Christopher Michael Pieczonka
Consultant or Advisory Role - Dendreon
Honoraria - Astellas Pharma; Dendreon
Research Funding - Astellas Pharma; Dendreon
Andrew Sandler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Janssen